New York, NY (PRWEB) February 12, 2013
The prescription drug information center DrugRisk.com is alerting those patients taking the blood thinner Pradaxa of new information added to the site which shows the popular drug might have a greater risk for fatal bleeding than anticoagulant alternatives.
“The goal of DrugRisk is to improve patient safety through education. This includes keeping consumers apprised of the latest drug warnings, recalls, studies and litigation news. Informed patients can discuss side effect options with their doctor and decide if they need legal advice,“ explains DrugRisk representative Ryan Mayer.
The resource center has previously reported that experts disagree about the risk for Pradaxa bleeding. The FDA recently issued an update that the drug carries the same risks as warfarin.* However, the Americal College of Cardiology has warned that Pradaxa use can significantly increase the risk of bleeding complications compared to warfarin.**
Now, DrugRisk has added new information from the Institute for Safe Medication Practices, which ranks anticoagulants like Pradaxa among the highest risk outpatient drugs. In reviewing hemorrhage cases submitted to the FDA, the institute also found bleeding from Pradaxa was nearly 5 times as likely to result in death than with warfarin.***
The drug resource center has learned that, due to the number of patients filing a Pradaxa lawsuit alleging bleeding, they are being consolidated in a special federal court in Illinois, formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
***Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf